Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique

Pharmazie

Volumn 64, Issue 5, 2009, Pages 301-310

  Pandita, Deepti ^a,c   Ahuja, A ^a   Velpandian, T ^b   Lather, V ^c   Dutta, T ^d   Khar, R K ^a  

^a HAMDARD UNIVERSITY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c UNIVERSITY OF MADEIRA   (Portugal)

^d DR H S GOUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; PACLITAXEL; PHOSPHATIDYLCHOLINE; POLOXAMER; SOLID LIPID NANOPARTICLE; STEARIC ACID; SURFACTANT; ANTINEOPLASTIC AGENT; EXCIPIENT; LIPID; NANOPARTICLE; SOLVENT;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; SURFACE CHARGE; THERMAL ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL; CHEMISTRY; DELAYED RELEASE FORMULATION; ELECTROCHEMISTRY; FREEZE DRYING; INFRARED SPECTROSCOPY; KINETICS; STOMACH; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; ELECTROCHEMISTRY; EXCIPIENTS; FREEZE DRYING; HUMANS; KINETICS; LIPIDS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLOXAMER; SOLVENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STOMACH; X-RAY DIFFRACTION;

EID: 70349234184     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.8338     Document Type: Article

References (25)

1. Betul AY, Jean-Pierre B, Lamprecht A (2006) Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug Dev Ind Pharm 32: 1089-1094.
2. Buckton G (1995) Interfacial phenomena in drug delivery and targeting. Harwood Academic Publishers.
3. Cavalli R (1998) The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a number of model molecules. Pharmazie 53: 392-396.
4. Cavalli R, Caputo O, Gasco MR (2000) Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci 10: 305-309.
5. Chen DB, Yang TZ, Lu WL, Zhang O (2001) In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 49: 1444-1447.
6. Crosasso P, Ceruti M, Brusa P, Arpicco S, Arpicco S, Cattel L (2000) Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release 63: 19-30.
7. Dong Y, Feng, S (2004) Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25: 2843-2849.
8. Feng S, Huang G (2001) Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers. J Control Release 71: 53-69.
9. Feng S. Mu L, Win KY, Huang G (2004) Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 11: 413-424.
10. Fonseca C, Simoes S, Gaspar R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83 : 273-286.
11. Gagandeep S, Novikoff PM, Ott M, Gupta S (1999) Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Lett 136: 109-118.
12. Hillery AM, Florence AT (1996) The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60 nm polystyrene particles after oral administration in the rat. Int J Pharm 132: 123-130.
13. Porter MR (1994) Handbook of Surfactants, Chapman & Hall, London.
14. Rao R, Diwan P, Prakash V (1998) Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev Ind Pharm 24: 327-336.
15. Schubert MA, Müller-Goymann CC (2003) Solvent injection as a new approach for manufacturing lipid nanoparticles - evaluation of the method and process parameters. Eur J Pharm Biopharm 55: 125-131.
16. Schwarz C, Mehnert W, Lucks JS, Müller RH (1994) Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 30: 83-96.
17. Singla AK, Garg A, Aggarwal D (2002) Paclitaxel and its formulations. Int J Pharm 235: 179-192.
18. Spencer CM, Faulds D (1994) Paclitaxel - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48: 794-847.
19. Szebeni J, Muggia FM, Alving CR (1998) Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90: 300-306.
20. Ten-Tije AJ, Verweij J, Loos WJ (2003) Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 42: 665-685.
21. Van-Tellingen O, Huizing MT, Panday VR (1999) Cremophor EL causes (pseudo) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81: 330-335.
22. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY (2007) Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 59: 491-504.
23. Wu G, Majewski J, Ege C, Kjaer K, Weygand MJ, Lee YCL (2005) Interaction between lipid monolayers and poloxamer 188: an X-ray reflectivity and diffraction study. Biophys J 89: 3159-3173.
24. Xu Z, Gu W, Huang J, Sui H, Zhou Z, Yang Y, Yan Z, Li Y (2005) In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm 288: 361-368.
25. Zur-Mühlen A (1996) Feste Lipid-Nanopartikel mit prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungsverhalten and -mechanismen [Dissertation]. Free University of Berlin, Germany.